Zemdri

Chemical Nameplazomicin
Dosage FormInjection (intravenous; 50 mg/mL containing plazomicin sulfate equivalent to 500 mg plazomicin free base)
Drug ClassAntibacterials
SystemUrinary
CompanyCipla USA
Approval Year2018

Indication

  • Zemdri is indicated for the treatment of patients 18 years of age or older with Complicated Urinary Tract Infections (cUTI) including Pyelonephritis.
Last updated on 10/16/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zemdri (plazomicin) Prescribing Information2018Cipla USA
Document TitleYearSource
Once-daily plazomicin for complicated urinary tract infections.2019New England Journal of Medicine